Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 1450 of 2051 entries
View as:

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

Phase: N/A Priority: Normal
NCT ID: NCT06445972 Org: User:
Start: 08/07/24 End: 10/27/28 Due: 10/27/29

A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007)

Phase: N/A Priority: Normal
NCT ID: NCT00231790 Org: User:
Start: 08/31/05 End: 10/31/06 Due: 10/31/07

A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)

Phase: N/A Priority: Normal
NCT ID: NCT06814132 Org: User:
Start: 04/07/25 End: 09/05/25 Due: 09/05/26

A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)

Phase: N/A Priority: Normal
NCT ID: NCT06894771 Org: User:
Start: 04/23/25 End: 10/02/29 Due: 10/02/30

A Study of Sotatercept (MK-7962) in Healthy Females Administered as a Liquid Formulation in an Autoinjector Versus the Lyophilized Formulation (MK-7962-027)

Phase: N/A Priority: Normal
NCT ID: NCT06930664 Org: User:
Start: 05/16/25 End: 01/30/26 Due: 01/30/27

An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035)

Phase: N/A Priority: Normal
NCT ID: NCT00635830 Org: User:
Start: 03/31/08 End: 04/30/08 Due: 04/30/09

ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00975507 Org: User:
Start: 03/31/98 End: 06/30/99 Due: 06/30/00

Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)

Phase: N/A Priority: Normal
NCT ID: NCT05158140 Org: User:
Start: 01/12/22 End: 02/21/23 Due: 02/21/24

Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)

Phase: N/A Priority: Normal
NCT ID: NCT05587712 Org: User:
Start: 01/19/23 End: 09/21/28 Due: 09/21/29

A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)

Phase: N/A Priority: Normal
NCT ID: NCT06460961 Org: User:
Start: 07/14/24 End: 07/13/29 Due: 07/13/30

Evaluation of Low Dose Infliximab in Ankylosing Spondylitis (Study P04352)

Phase: N/A Priority: Normal
NCT ID: NCT00202865 Org: User:
Start: 05/01/05 End: 05/01/07 Due: 05/01/08

Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)

Phase: N/A Priority: Normal
NCT ID: NCT03930615 Org: User:
Start: 06/21/19 End: 03/16/22 Due: 03/16/23

Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011)

Phase: N/A Priority: Normal
NCT ID: NCT00432523 Org: User:
Start: 01/20/05 End: 09/05/05 Due: 09/05/06

Lipid Management in Clinical Practice (MK-0524A-115)

Phase: N/A Priority: Normal
NCT ID: NCT01071278 Org: User:
Start: 10/31/09 End: 02/28/11 Due: 02/28/12

A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C

Phase: N/A Priority: Normal
NCT ID: NCT00118768 Org: User:
Start: 08/31/05 End: - Due: -

A Pharmacokinetic Study to Evaluate the Effect of MAALOX on Raltegravir (MK-0518) in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-295)

Phase: N/A Priority: Normal
NCT ID: NCT01930045 Org: User:
Start: 10/01/13 End: 12/10/13 Due: 12/10/14

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021)

Phase: N/A Priority: Normal
NCT ID: NCT01717300 Org: User:
Start: 11/06/12 End: 10/29/14 Due: 10/29/15

Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis

Phase: N/A Priority: Normal
NCT ID: NCT00629941 Org: User:
Start: 03/31/08 End: - Due: -

A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of MK-1064 (MK-1064-001)

Phase: N/A Priority: Normal
NCT ID: NCT02549014 Org: User:
Start: 07/06/09 End: 09/29/09 Due: 09/29/10

Safety and Efficacy of PegIntron Plus Rebetol in Patients With Chronic Hepatitis C in Japan, Excluding (1) Subjects With HCV Genotype 1 and High Viral Load, and (2) Interferon-naïve Subjects With Low Viral Load (Study P04841)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00724230 Org: User:
Start: 02/28/06 End: 12/31/08 Due: 12/31/09

A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00727961 Org: User:
Start: 11/09/04 End: 01/10/08 Due: 01/10/09

Effect of MK0524A on Cholesterol Levels (0524A-048)

Phase: N/A Priority: Normal
NCT ID: NCT00536510 Org: User:
Start: 04/30/07 End: 03/31/08 Due: 03/31/09

Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)

Phase: N/A Priority: Normal
NCT ID: NCT02255097 Org: User:
Start: 10/24/14 End: 06/18/21 Due: 06/18/22

A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)

Phase: N/A Priority: Normal
NCT ID: NCT00539968 Org: User:
Start: 06/30/07 End: 12/31/09 Due: 12/31/10

Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)

Phase: N/A Priority: Normal
NCT ID: NCT00073450 Org: User:
Start: 09/30/03 End: 06/30/04 Due: 06/30/05